Apr 27, 2026 08:37AM
Apr 27, 2026 08:30AM
Mar 3, 2026 08:00AM
Feb 17, 2026 08:38AM
Feb 17, 2026 08:30AM
Feb 12, 2026 08:03AM
Feb 12, 2026 08:00AM Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
Jan 29, 2026 08:04AM
Jan 29, 2026 08:00AM
Jan 27, 2026 08:04AM
Jan 27, 2026 08:00AM
Jan 20, 2026 08:04AM
Jan 20, 2026 08:00AM
Jan 7, 2026 08:01AM Aspire Biopharma receives FDA guidance for sublingual aspirin drug
Jan 7, 2026 08:00AM
Dec 4, 2025 09:04AM
Dec 4, 2025 09:00AM
Dec 2, 2025 09:00AM
Oct 3, 2025 11:30AM
Oct 1, 2025 08:32AM
Oct 1, 2025 08:30AM Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED
Sep 3, 2025 08:31AM
Aug 18, 2025 08:30AM
Jun 24, 2025 08:30AM
Jun 10, 2025 08:34AM
Jun 10, 2025 08:30AM
May 28, 2025 08:30AM
May 20, 2025 08:30AM Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Apr 29, 2025 08:30AM
Apr 14, 2025 08:30AM
Apr 9, 2025 08:30AM
Mar 20, 2025 08:30AM
Mar 13, 2025 08:33AM
Mar 13, 2025 08:30AM
Feb 25, 2025 07:33AM Aspire Biopharma Holdings (ASBP) Provides an Update on Lead Product Candidate
Feb 25, 2025 07:30AM
Feb 20, 2025 06:15PM

322,963 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All